Add-on therapies fail to beat placebo in cutaneous sarcoidosis, but quality of life may improveCorticosteroids Show Limited Success for Skin Sarcoidosis Treatment

Acta dermato-venereologica Published September 8, 2026 Study authors: Thianich Felicia C, Wörgötter Katharina M, Bruckner Linda, Grübler Martin R, Posch Christian PubMed ↗ DOI ↗ Editorial oversight: Dr. Amelia Tan, PhD · Internal Medicine & Chronic Disease

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway

Interpret add-on therapy results cautiously; no significant clinical benefit, but possible quality-of-life trend.

This meta-analysis pooled data from 156 adults with cutaneous sarcoidosis to evaluate the efficacy of pharmacological add-on therapies compared with placebo. The primary outcome was clinical response, with secondary outcomes including quality of life and serious adverse events. The analysis found no significant improvement in clinical response with add-on therapy (OR 2.24; 95% CI, 0.73-6.90; p=0.16). There was a non-significant trend toward improved quality of life (OR 2.23; 95% CI, 0.87-5.73; p=0.09). No significant difference in serious adverse events was observed between groups.

The authors note that the risk of bias in the included trials ranged from moderate to high, and the overall evidence from randomized controlled trials is limited. These limitations reduce confidence in the findings. The meta-analysis did not report details on follow-up duration, adverse events, or discontinuations, which further limits interpretation.

In practice, these results suggest that pharmacological add-on therapies may not provide significant clinical benefit beyond corticosteroids for cutaneous sarcoidosis. However, the potential trend toward improved quality of life warrants consideration, though it did not reach statistical significance. Clinicians should weigh the lack of clear efficacy against possible benefits in individual patients, while acknowledging the uncertainty in the evidence.

How this fits prior evidence

This meta-analysis addresses a gap in evidence for cutaneous sarcoidosis, where prior coverage focused on corticosteroids in other conditions. It extends the discussion by showing that add-on therapies do not significantly improve clinical response (OR 2.24; 95% CI, 0.73-6.90; p=0.16), contrasting with findings in knee osteoarthritis where ozone injections outperformed corticosteroids. It also aligns with the lack of benefit seen with adjunctive corticosteroids in herpes simplex encephalitis, reinforcing that not all add-on therapies yield clear benefits.

Researchers looked at how different treatments work for adults with cutaneous sarcoidosis, a condition that causes skin inflammation. The study specifically looked at whether adding extra medications to a standard corticosteroid treatment would improve the condition.

The analysis included data from 156 patients. The results showed that these additional medications did not provide a significant improvement in clinical response compared to using a placebo. While there was a slight trend toward better quality of life for some patients, this change was not statistically significant.

Because the evidence from high-quality trials is limited and the risk of bias was high, these results should be viewed with caution. For now, the data suggests that adding extra drugs to corticosteroids does not reliably improve the physical symptoms of skin sarcoidosis. Patients should talk to their doctors about the best long-term management plan for their specific needs.

What this means for you:

Adding extra medications to corticosteroids may not improve clinical outcomes for skin sarcoidosis.

Common questions

Do extra medications help skin sarcoidosis?

The study found that adding extra medications to a corticosteroid treatment did not show a significant improvement in clinical response compared to a placebo. While there was a slight trend toward better quality of life, it was not statistically significant. You should discuss your specific treatment plan with your doctor.

Is it safe to add medications to my steroid treatment?

The study reported no significant difference in serious adverse events between the group receiving extra medications and the group that did not. However, because the evidence from high-quality trials is limited, you should consult your healthcare provider regarding safety and your specific medical history.

What did the study find about quality of life?

The study found a non-significant trend toward improved quality of life for patients receiving extra medications. Because this result was not statistically significant, it means the data is not strong enough to confirm that these extra treatments definitely improve daily life.

Study Details

Study typeMeta analysis

Sample sizen = 156

EvidenceLevel 1

PublishedSep 2026

PMID42708647

View Original Abstract ↓

Cutaneous sarcoidosis is a granulomatous skin disease associated with significant quality-of-life impairment. Evidence from randomized controlled trials (RCTs) guiding systemic or targeted therapy remains limited. To assess the efficacy and safety of pharmacological therapies for cutaneous sarcoidosis in randomized placebo-controlled trials PubMed, the Cochrane Library, and ClinicalTrials.gov were searched through January 2025. Eligible studies were RCTs including adults with cutaneous sarcoidosis randomized to pharmacological therapy versus placebo. Outcomes were clinical response, quality of life, and serious adverse events (SAEs). Pooled odds ratios (ORs) with 95 % confidence intervals (CIs) were calculated using random-effects models. Six RCTs including 156 participants were analyzedanalysed. Pharmacological therapies did not significantly improve clinical response compared with placebo (OR 2.24; 95% CI, 0.73-6.90; p=0.16). A non-significant trend toward improved quality of life was observed (OR 2.23; 95% CI, 0.87-5.73; p=0.09). No significant difference in SAEsserious adverse events was found between groups (OR 0.97; 95% CI, 0.48-1.96; p=0.93). Risk of bias ranged from moderate to high, with low statistical heterogeneity. Pharmacological add-on therapies showed no significant efficacy beyond corticosteroids but may improve quality of life. Larger, well-designed RCTs are needed.

Add-on therapies fail to beat placebo in cutaneous sarcoidosis, but quality of life may improveCorticosteroids Show Limited Success for Skin Sarcoidosis Treatment

How this fits prior evidence

Common questions

Study Details

Budesonide-glycopyrronium-formoterol fumarate dihydrate improved lung function and reduced severe exacerbations versus budesonide-formoterol in inadequately controlled asthma

New Asthma Drug Cuts Attacks Without Recent Crisis

Clinical research that matters. Delivered to your inbox.

Add-on therapies fail to beat placebo in cutaneous sarcoidosis, but quality of life may improveCorticosteroids Show Limited Success for Skin Sarcoidosis Treatment

How this fits prior evidence

Common questions

More on Cutaneous sarcoidosis

Study Details

Budesonide-glycopyrronium-formoterol fumarate dihydrate improved lung function and reduced severe exacerbations versus budesonide-formoterol in inadequately controlled asthma

New Asthma Drug Cuts Attacks Without Recent Crisis

Clinical research that matters. Delivered to your inbox.

Related in Allergy & Immunology

From Other Specialties